GMAB vs MTD: fair value comparison
Genmab A/S and Mettler-Toledo International Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, MTD currently sits closer to the top of our discount ranking. GMAB carries the stronger quality grade.
| GMAB | MTD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $28.68 | $1,345.26 |
| 12-month range | $25.45–$33.27 | $1,183.57–$1,468.09 |
| Sector rank | #48 of 113 Healthcare | #47 of 113 Healthcare |
| Quality grade | A | B |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Declining |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Undervalued | — |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: GMAB fair value analysis · MTD fair value analysis